Wegovy
Generic name: semaglutide
Manufactured by: Novo Nordisk
Therapeutic category: Obesity
Tariff Status Explanation
The manufacturer has signed an MFN pricing and onshoring agreement with the US government. This drug carries a 0% tariff rate under the Annex III agreement.
Key Dates
July 31, 2026
Annex III company tariff effective date (0% rate)
What Can You Do?
- →Ask your doctor if a generic or biosimilar equivalent is available. Generics are fully exempt from all tariffs.
- →Check if your manufacturer has signed an MFN deal. View all MFN deals →
- →Use our Savings Guide to find discount programs, patient assistance, and alternatives before tariffs take effect.
Will Wegovy Cost More Due to Tariffs?
Wegovy (semaglutide) is manufactured by Novo Nordisk and is classified as a obesity medication. Novo Nordisk is one of the 13 Annex III companies that signed MFN pricing and onshoring agreements with the US government. As a result, Wegovy carries a 0% tariff rate under the Section 232 pharmaceutical proclamation, effective July 31, 2026.
Remember that the tariff applies to the drug's acquisition cost — the price pharmacies pay to purchase the drug — not necessarily your final copay. Patients with insurance may see the tariff impact appear gradually through formulary changes or premium increases. Uninsured patients and those paying cash prices may see more direct impacts.